Fig 1: FGFR1, FGFR2, and FGFR3 transcript and protein levels together with FGFRs variants and FGFR1 amplification status. Heat maps illustrate the (a) FGFR1-3 relative gene expression values (mRNA) with differentiation for RT-PCR and NGS methods; (b) FGFR1-3 protein expression levels based on H-score; (c) FGFRs variants occurrence with differentiation for clinical significance and FGFRs fusions; (d) FGFR1 amplification status based on FGFR1/CEN8 ≥ 2.0 or the average number of FGFR1 signals per cell ≥ 6 or ≥10% of tumor cells containing ≥ 15 FGFR1 signals or large clusters; for Sq-NSCLC samples. The largest gene expression values (a,b) are displayed in red color, intermediate values in shades of orange and yellow, and the smallest values in light yellow. Dark colored cells in the map (c,d) represent the variants, fusion, or an FGFR1 amplification occurrence, while no FGFRs variants, fusion, or amplification occurrence is indicated in light yellow. Not analyzed cells are indicated in white.
Fig 2: Patterns of FGFR1, FGFR2, and FGFR3 expression via immunohistochemistry (IHC) in selected Sq-NSCLC samples (magnification, ×100; scale bars, 100 μm). Staining intensity (described in the Materials and Methods) was stratified according to: a four-graded scale: negative (IHC = 0), weak (IHC = 1), moderate (IHC = 2), and strong (IHC = 3); and H-score determined as follows: 0 x (% cells with no staining [0]) + 1 × (% cells staining faint, weakly [1+]) + 2 × (% cells staining moderately [2+]) + 3 × (% cells staining strongly [3+]).
Fig 3: Correlation scatter plot of the FGFR1 gene expression assessed by RT-PCR and NGS (Archer Lung FusionPlex) in 40 Sq-NSCLC tumor samples. Corresponding figures for FGFR2 and FGFR3 gene expression are shown in Supplementary Figure S2.
Fig 4: Relative expression of (a) FGFR1; (b) FGFR2; (c) FGFR3; (d) FGFR4 genes in Sq-NSCLC tumor and tumor-adjacent normal tissues. Significant differences of FGFR1 and FGFR4 expression are indicated in red.
Supplier Page from Abcam for Anti-FGFR2 antibody